DUBLIN--(BUSINESS WIRE)--The "Indian Peptides and Heparin Market by Type (Insulin, Teriparatide, Liraglutide, Leuprolide, Leuprolide, Exenatide, Calcitonin, Enaxaparin Sodium, Heparin Sodium), Application (Diabetes, Infectious Diseases, Cancer, Osteoporosis) - Forecast to 2022" report has been added to Research and Markets' offering.
The Indian peptides market is expected to reach USD 883.0 million in 2022 from USD 381.8 million in 2016 and is expected to register a CAGR of 15.0%, and the Indian heparin market is projected to reach USD 170.2 million by 2022, at a CAGR of 4.9%.
Factors such as increasing prevalence of chronic diseases, increasing incidence of coagulation disorder, and favorable government policies are the major driving factors for the Indian peptides and heparin market. On the other hand, the availability of alternative drugs is the major restraining factor for the Indian peptides market.
The patent expiry of blockbuster drugs will provide growth opportunities to players in the Indian peptides market. For example, Victorza is the brand name of the liraglutide peptide developed by Novo Nordisk. Its patent will expire in August 2017, which will enable drug manufacturers to introduce their generic versions of it.
Key Topics Covered:
1 Indian Peptides Market Overview
2 Indian Peptides Market, By Type
3 Indian Peptides Market, By Application
4 Indian Peptides Market Share Analysis
5 Indian Peptides Market Company Profiles
6 Indian Heparin Market Overview
7 Indian Heparin Market, By Type
8 Indian Heparin Market Share Analysis
9 Indian Heparin Market Company Profiles
- Bharat Biotech
- Bharat Serum and Vaccines Limited
- Biocon Limited
- Biological E Limited
- Celon Laboratories Pvt. Ltd.
- Cipla Limited
- Cipla Ltd.
- Dr. Reddy's Laboratories
- Emcure Pharmaceuticals Pvt. Ltd.
- Gland Pharma Limited
- Intas Pharmaceuticals Ltd.
- Natco Pharma Limited
- Samarth Life Sciences Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Troikaa Pharmaceuticals Ltd.
- United Biotech (P) Limited
- VHB Life Sciences Limited
- Wockhardt Ltd.
- Zydus Cadila
For more information about this report visit https://www.researchandmarkets.com/research/lkdqmb/indian_peptides
